清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract P5-12-08: Single-center experience in antibody drug conjugate sequencing in HER2-low metastatic breast cancer

作者
Utsav Joshi,Junmin Whiting,Mo Qianxiang,Melissa Armitage,Jorge Ávila,Kimberley T. Lee,Avan J. Armaghani,Tracey O'Conner,Ricardo Lima Barros Costa,Aixa Soyano Muller,Loretta Loftus,Hatem H. Soliman,Hyo Sook Han
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:31 (12_Supplement): P5-12 被引量:2
标识
DOI:10.1158/1557-3265.sabcs24-p5-12-08
摘要

Abstract Introduction: Two antibody-drug conjugates (ADCs), trastuzumab deruxtecan (T-Dxd) and sacituzumab govitecan (SG), were approved by the FDA for HER2 low and HER2 negative metastatic breast cancer (MBC) respectively and the current data of the optimal sequencing of ADCs is limited. This study evaluated the efficacy of the second ADC (ADC2) following the first ADC (ADC1) in HER2-low MBC patients (pts) who have received both ADCs of T-Dxd and SG. Methods: This study represents an IRB approved retrospective cohort study of adult pts (age ≥ 18 years) at Moffitt Cancer Center between December 1, 2019, to January 31, 2024 with HER2-low MBC treated with both ADCs. Data was obtained via abstraction of the electronic medical record. The primary objective was to evaluate progression free survival (PFS) after ADC 1 (PFS1) and after ADC2 (PFS2). PFS is defined as the time from first dose of ADC to time of imaging showing progression or death. The Kruskal-Wallis test was applied to assess the association between continuous and categorical variables, while the Chi-square test or Fisher's exact test was used to evaluate the association between two categorical variables. All statistical tests were two-sided, with a significance level set at p < 0.05. Results: Overall, 34 pts met inclusion criteria. Seventeen pts received T-Dxd as ADC1 and 17 patients received SG as ADC1. The cohort included one male patient, 41.2% (14/34) were hormone receptor (HR) positive, and 58.8% (20/34) were triple negative breast cancer (TNBC) from metastatic biopsy. Two of the patients with TNBC MBC had ER or PR positive ≤ 10%. Two of the 34 patients were still receiving ongoing therapy with ADC2 at the time of the data cutoff. All of the HR positive subgroup received T-Dxd first followed by SG, and most TNBC patients (85%) received SG first followed by T-Dxd. Overall median PFS1 (mPFS1) with ADC1 in all comers was 5.8mo, and median PFS2 (mPFS2) with ADC2 was 2.4mo. PFS1 and PFS2 by drug sequence can be seen in table 1. Eight patients had significantly longer PFS2, defined as having received at least 8 cycles of therapy, and six of these patients received T-Dxd as ADC2. Five of the eight pts with this longer PFS2 were TNBC at the initial diagnosis and remained TNBC at time of ADC treatment. The other three pts were TNBC at initial diagnosis and changed to HR positive disease at time of ADC treatment. 67.6% (n=23) of pts received ADC therapies back-to-back with no lines of therapy in between, while 20.6% (n=35) of pts received one line of therapy in between ADCs. mPFS1 for those who received back-to-back therapy was 5.8mo while those with one line of therapy in between had a mPFS1 of 4.3mo. Of the 7 pts with brain metastases at start of ADC1, mPFS1 was 8.5mo. Of the 10 pts with brain metastases at the start of ADC2, mPFS2 was 2.9mo. Ten (29.4%) pts experienced any grade 2 or above adverse events (AEs) with ADC1, while 12 (35.3%) pts experienced any grade 2 AEs with ADC2. Further description of AEs will be discussed at the presentation. Conclusion: Our data demonstrates that mPFS is shorter following ADC2 which is consistent with limited available data to date. Interestingly, there were 8 pts with prolonged PFS2 of over 6 months, having received 8 or more cycles of therapy prior to progression. Overall, our study is limited by its retrospective nature and small sample size. Citation Format: Utsav Joshi, Junmin Whiting, Mo Qianxiang, Melissa Armitage, Jorge Avila, Kimberley T. Lee, Avan Armaghani, Tracey O'Conner, Ricardo Costa, Aixa Soyano Muller, Loretta Loftus, Hatem Soliman, Hyo S. Han. Single-center experience in antibody drug conjugate sequencing in HER2-low metastatic breast cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P5-12-08.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
11秒前
大医仁心完成签到 ,获得积分0
12秒前
潇洒小海豚完成签到,获得积分10
14秒前
23秒前
40秒前
44秒前
淡定的夜云完成签到 ,获得积分10
48秒前
51秒前
56秒前
圈圈圆了发布了新的文献求助100
58秒前
59秒前
1分钟前
顺心的一德完成签到,获得积分10
1分钟前
圈圈圆了完成签到,获得积分10
1分钟前
1分钟前
yc关闭了yc的文献求助
1分钟前
1分钟前
amiee发布了新的文献求助10
1分钟前
高高从霜完成签到 ,获得积分10
1分钟前
1分钟前
开朗的尔蝶的应助被amiee采纳,获得10
2分钟前
2分钟前
冷酷冬卉完成签到,获得积分10
2分钟前
2分钟前
whc发布了新的文献求助10
2分钟前
2分钟前
2分钟前
小星河完成签到 ,获得积分10
2分钟前
itsnotover发布了新的文献求助10
2分钟前
3分钟前
itsnotover完成签到,获得积分10
3分钟前
3分钟前
3分钟前
3分钟前
007关注了科研通微信公众号
3分钟前
007关注了科研通微信公众号
3分钟前
搞怪的白云完成签到 ,获得积分0
3分钟前
3分钟前
3分钟前
充电宝的应助被007采纳,获得30
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190159
求助须知:如何正确求助?哪些是违规求助? 9577264
关于积分的说明 21852314
捐赠科研通 7788621
什么是DOI,文献DOI怎么找? 3436279
关于科研通互助平台的介绍 2560058
邀请新用户注册赠送积分活动 2482880